What side effects are associated with this type of intervention?

The most common treatments for smoking cessation include transdermal nicotine patches and pharmacotherapies like varenicline. Transdermal nicotine patches can cause side effects such as skin irritation, dizziness, and sleep disturbances. Varenicline is associated with nausea, insomnia, and vivid dreams. While these treatments are generally more effective than placebo, patients should discuss potential side effects with their healthcare provider to make an informed decision.

What prior FDA approvals exist?

The FDA has approved several pharmacologic treatments for smoking cessation, including varenicline, bupropion, and various forms of nicotine replacement therapies (NRTs) such as patches, gums, and lozenges. These treatments have been shown to be effective in increasing smoking cessation rates in numerous clinical trials. Additionally, digital and mobile health interventions are being explored as complementary approaches, although specific FDA approvals for these newer methods were not detailed.

What other types of research exist?

Promising novel alternatives to ETM Purchase for smoking cessation include telemedicine-based smoking cessation programs, which have shown similar efficacy to face-to-face programs. Additionally, technology-enhanced delivery methods such as smartphone applications and online CBT-based interventions have demonstrated effectiveness in supporting smoking cessation. These methods offer flexibility and accessibility, making them suitable for patients who may face barriers to traditional in-person treatments.

← Back to Search

Reat ETM and Hypothetical ETM for Smoking/Cigarette Smoking

N/A

Waitlist Available

Led By Roberta Freitas-Lemos, Ph.D.

Research Sponsored by Virginia Polytechnic Institute and State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 day

Awards & highlights

No Placebo-Only Group

Summary

This trial studies how smokers decide to buy cigarettes when prices increase.

Who is the study for?

This trial is for individuals who are at least 21 years old, have been smoking consistently for the past three months, and smoke a minimum of five cigarettes daily. They must not use other tobacco products often, be able to give informed consent, and have internet access. People with uncontrolled health issues or those planning to quit smoking soon cannot participate.

What is being tested?

The study is examining two methods related to cigarette smoking: in-lab and remote procedures using both hypothetical and real ETM (presumably a measure related to tobacco use) purchase outcomes. It aims to see if these different settings yield comparable results.

What are the potential side effects?

Since this trial involves behavioral assessments rather than medical treatments, traditional side effects like you might expect from drugs are not applicable here.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 day

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 day

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 day for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Cigarette demand

Nicotine/tobacco products substitution

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Group I: Remote proceduresExperimental Treatment2 Interventions

Exclusive cigarette smokers will be recruited and will experience all study procedures remotely.

Group II: In-lab proceduresExperimental Treatment2 Interventions

Exclusive cigarette smokers will be recruited and will experience all study procedures in the laboratory.

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for smoking cessation include pharmacological and behavioral approaches. Pharmacological treatments like varenicline and bupropion target nicotine receptors in the brain to reduce cravings and withdrawal symptoms. Varenicline acts as a partial agonist at nicotinic acetylcholine receptors, while bupropion inhibits the reuptake of norepinephrine and dopamine. Behavioral approaches, such as cognitive-behavioral therapy (CBT) and motivational interviewing (MI), focus on changing smoking-related behaviors and thought patterns. These treatments are crucial for smoking patients as they address both the physical and psychological aspects of addiction, enhancing the chances of successful cessation.

[Cigarette smoking. A pilot project of dehabituation and experimental research].Remote Methods for Conducting Tobacco-Focused Clinical Trials.Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review.